Yahoo Finance Today’s Research Reports on Aurinia Pharmaceuticals, Crescita Therapeutics, CanniMed Therapeutics and Titan Medical
NEW YORK, NY / ACCESSWIRE / February 20, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
Aurinia Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=AUP.TO
Crescita Therapeutics Inc.
https://rdinvesting.com/news/?ticker=CTX.TO
CanniMed Therapeutics Inc.
https://rdinvesting.com/news/?ticker=CMED.TO
Titan Medical Inc.
https://rdinvesting.com/news/?ticker=TMD.TO
Aurinia Pharmaceuticals' stock edged 0.30% lower Friday, to close the day at $6.57. The stock recorded a trading volume of 16,882 shares, which was below its three months average volume of 60,945 shares. In the last year, Aurinia Pharmaceuticals' shares have traded in a range of 4.25 - 14.17. The share price has gained 54.59% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $6.64 is below its 200-day moving average of $7.16. Shares of Aurinia Pharmaceuticals have gained approximately 14.86 percent year-to-date.
Access RDI's Aurinia Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AUP.TO
On Friday, shares of Crescita Therapeutics recorded a trading volume of 8,517 shares, which was below the three months average volume of 33,353 shares. The stock ended the day flat at 0.65. The share price has gained 35.42% from its 52-week low with a 52-week trading range of 0.48 - 1.20. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.63 is at its 200-day moving average of $0.63. Shares of Crescita Therapeutics have gained approximately 18.18 percent year-to-date.
Access RDI's Crescita Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CTX.TO
CanniMed Therapeutics' stock moved 4.38% lower Friday, to close the day at $33.60. The stock recorded a trading volume of 203,837 shares, which was below its three months average volume of 478,458 shares. In the last year, CanniMed Therapeutics' shares have traded in a range of 7.32 - 46.00. The share price has gained 359.02% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $31.86 is greater than its 200-day moving average of $18.16. Shares of CanniMed Therapeutics have gained approximately 49 percent year-to-date.
Access RDI's CanniMed Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CMED.TO
On Friday, shares of Titan Medical recorded a trading volume of 348,820 shares, which was below the three months average volume of 773,103 shares. The stock ended the day flat at 0.32. The share price has gained 142.31% from its 52-week low with a 52-week trading range of 0.13 - 0.68. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.42 is greater than its 200-day moving average of $0.35. Shares of Titan Medical have fallen approximately 16 percent year-to-date.
Access RDI's Titan Medical Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TMD.TO
Our Actionable Research on Aurinia Pharmaceuticals Inc. (TSX:AUP.TO), Crescita Therapeutics Inc. (TSX:CTX.TO), CanniMed Therapeutics Inc. (TSX:CMED.TO) and Titan Medical Inc. (TSX:TMD.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
